Gabriela Sanchez-Zuno
Associate Research ScientistCards
About
Research
Publications
2025
Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1
Tran T, Sánchez-Zuno G, Osmani L, Caulfield J, Valdez C, Piecychna M, Leng L, Armstrong M, Donnelly S, Bifulco C, Clister T, Kulkarni R, Zhang L, Sznol M, Jilaveanu L, Kluger H, Kang I, Bucala R. Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1. JCI Insight 2025, 10: e191539. PMID: 41122966, PMCID: PMC12581657, DOI: 10.1172/jci.insight.191539.Peer-Reviewed Original ResearchConceptsAnti-PD-1Macrophage migration inhibitory factorAnti-MIFMigration inhibitory factorTumor growthTherapeutic efficacyAnti-programmed cell death 1Intratumoral immune cell populationsAssociated with advanced diseaseHigh-expression MIF allelesCell death 1Inhibitory factorTh1 cytokine levelsInhibition of macrophage migration inhibitory factorDual inhibitionMurine tumor modelsColorectal cancer modelImmune cell populationsTumor-bearing animalsClinical trial developmentMultiple cancer typesAntitumor responseDeath-1PD-1Tumor burdenMIF as an oncogenic driver of low‐heterogeneity melanomas
Tran T, Sánchez‐Zuno G, Kulkarni R, Kluger H, Bucala R. MIF as an oncogenic driver of low‐heterogeneity melanomas. Molecular Oncology 2025, 19: 1295-1298. PMID: 40131169, PMCID: PMC12077282, DOI: 10.1002/1878-0261.70031.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorImproving therapeutic outcomesMigration inhibitory factorPotential therapeutic utilityImmune landscapeMelanoma clonesImmune escapeT cellsImmunoregulatory cytokinesTumor heterogeneityTumor progressionOncogenic driversPathway inhibitorTherapeutic outcomesTumor evolutionInhibitory factorCell proliferationMelanomaTumorCellsAntagonistCytokinesDistinctive Macrophage Migration Inhibitory Factor Receptor Patterns and Soluble Biomarkers in Rheumatoid Arthritis: Unveiling Key Associations with Disease Activity
Sánchez-Zuno G, Bucala R, Hernández-Bello J, Palafox-Sánchez C, Vizcaíno-Quirarte A, Muñoz-Valle J. Distinctive Macrophage Migration Inhibitory Factor Receptor Patterns and Soluble Biomarkers in Rheumatoid Arthritis: Unveiling Key Associations with Disease Activity. Journal Of Interferon & Cytokine Research 2025, 45: 99-106. PMID: 39914814, PMCID: PMC12021775, DOI: 10.1089/jir.2024.0184.Peer-Reviewed Original ResearchConceptsMigration inhibitory factorMigration inhibitory factor levelsDisease activityRA patientsControl subjectsRheumatoid arthritisLevels of migration inhibitory factorSerum levels of CXCL12Levels of CXCL12Serum of RA patientsModerate disease activityMembranous expression patternRheumatoid factor titerMIF levelsCXCL12 levelsSerum levelsCXCL8 levelsSoluble biomarkersTreatment protocolsPattern of expressionSerum CXCL8PatientsReceptor patternsClinical biomarkersInhibitory factorPtpA protein from Mycobacterium avium subsp. paratuberculosis as a potential marker of rheumatoid arthritis in humans
Hernández-Bello J, Bach H, Cerpa-Cruz S, Sánchez-Zuno G, Hernández-Gutiérrez R, Nicoletti F, Saraceno A, Muñoz-Valle J. PtpA protein from Mycobacterium avium subsp. paratuberculosis as a potential marker of rheumatoid arthritis in humans. PLOS ONE 2025, 20: e0316727. PMID: 39752467, PMCID: PMC11698356, DOI: 10.1371/journal.pone.0316727.Peer-Reviewed Original ResearchConceptsMycobacterium avium subspecies paratuberculosisControl subjectsVirulence factorsRA patientsBattery of virulence factorsRheumatoid arthritisProtein tyrosine phosphatase ADisease activityPhago-lysosome fusionModerate to high disease activityHigh disease activityDisease Activity ScoreMale control subjectsIndirect ELISA methodMycobacterium avium subspecies paratuberculosis infectionMycobacterium avium subspPhosphatase AMarkers of rheumatoid arthritisIntracellular pathogensPTPAMedian ODActivity scoreProteinELISA methodPatients
2024
571 Dual inhibition of MIF and DDT enhances the efficacy of anti-PD-1 therapy in murine melanoma
Sánchez-Zuno G, Valdez C, Osmani L, Kang I, Bucala R, Tran T. 571 Dual inhibition of MIF and DDT enhances the efficacy of anti-PD-1 therapy in murine melanoma. 2024, a651-a651. DOI: 10.1136/jitc-2024-sitc2024.0571.Peer-Reviewed Original Research763 Therapeutic targeting of the MIF/DDT-CD74 axis in head and neck squamous cell carcinoma (HNSCC) murine models
Valdez C, Sánchez-Zuno G, Mahajan A, Trosch W, Burtness B, Bucala R, Tran T. 763 Therapeutic targeting of the MIF/DDT-CD74 axis in head and neck squamous cell carcinoma (HNSCC) murine models. 2024, a867-a867. DOI: 10.1136/jitc-2024-sitc2024.0763.Peer-Reviewed Original ResearchComplex Thinking Abilities in the Rapidly Evolving Field of Genomics and Personalized Medicine: Analysis of Actionability on Cancer with ChatGPT and Literature
RAMÍREZ- MONTOYA M, SANCHEZ- ZUNO G, GONZALEZ R, CASILLAS- MUNOZ F. Complex Thinking Abilities in the Rapidly Evolving Field of Genomics and Personalized Medicine: Analysis of Actionability on Cancer with ChatGPT and Literature. The Eurasia Proceedings Of Science Technology Engineering And Mathematics 2024, 28: 34-46. DOI: 10.55549/epstem.1519145.Peer-Reviewed Original ResearchPrognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
Valdez C, Sánchez-Zuno G, Osmani L, Ibrahim W, Galan A, Bacchiocchi A, Halaban R, Kulkarni R, Kang I, Bucala R, Tran T. Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma. Oncotarget 2024, 15: 507-520. PMID: 39028303, PMCID: PMC11259151, DOI: 10.18632/oncotarget.28615.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkers, TumorFemaleHistocompatibility Antigens Class IIHumansImmune Checkpoint InhibitorsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMelanomaMiddle AgedMutationPrognosisRetrospective StudiesSkin NeoplasmsConceptsMacrophage migration inhibitory factorImmune checkpoint inhibitionD-dopachrome tautomeraseExpression of macrophage migration inhibitory factorDrivers of tumor progressionInflammatory cell markersPatient tumor samplesPatient survival outcomesMigration inhibitory factorStatistically significant differenceCheckpoint inhibitionImmune therapyPrognostic valueSurvival outcomesResistant melanomaGene expressionImproved survivalRetrospective studyInflammatory markersTumor progressionCell markersTumor samplesClinical evidenceMelanomaBulk RNA sequencingAutoimmune biomarkers in Rheumatoid arthritis: A clinical and environmental approach
Martínez-Pulido R, Sánchez-Zuno G, Matuz-Flores M, Rosas-Rodríguez J, Pacheco-Tena C, Muñoz-Valle J. Autoimmune biomarkers in Rheumatoid arthritis: A clinical and environmental approach. Clinica Chimica Acta 2024, 558: 119033. DOI: 10.1016/j.cca.2024.119033.Peer-Reviewed Original ResearchMacrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities
Valdez C, Sánchez-Zuno G, Bucala R, Tran T. Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities. International Journal Of Molecular Sciences 2024, 25: 4849. PMID: 38732068, PMCID: PMC11084905, DOI: 10.3390/ijms25094849.Peer-Reviewed Original ResearchConceptsInhibition of MIFResponse to infectionNon-canonical signaling pathwaysClinical studiesCancer patientsClinical trialsInflammatory cytokinesDriving tumorigenesisClinical explorationCancer typesCancerDual inhibitionTherapeutic targetIn vivoIn vitroSignaling pathwayMIFAntitumor candidateBinding partners